Bay­er claims an­oth­er win on its CKD and di­a­betes hope­ful, though the ques­tion re­mains over just how big it is

Af­ter earn­ing pri­or­i­ty re­view for a top CKD and di­a­betes pro­gram back in Jan­u­ary, Bay­er is re­veal­ing more da­ta that it hopes will boost its pitch to reg­u­la­tors.

Bay­er’s finerenone has passed an­oth­er Phase III test, the phar­ma an­nounced Mon­day, say­ing the can­di­date met the pri­ma­ry end­point in a sec­ond study eval­u­at­ing treat­ment for CKD and type 2 di­a­betes. The dif­fer­ence here is this study in­clud­ed more pa­tients with ear­li­er stages of the dis­ease than the first tri­al.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.